Pathogen | Parenteral agents | Oral agents |
Staphylococcus aureus | ||
Methicillin-susceptible | Cefazolin Nafcillin Oxacillin | Cephalexin Cloxacillin (not available in the United States) Dicloxacillin Clindamycin* |
Methicillin-resistant | ||
Clindamycin-susceptible | Vancomycin Clindamycin | Clindamycin |
Clindamycin-resistant¶ | Vancomycin Linezolid DaptomycinΔ | Linezolid Trimethoprim-sulfamethoxazole |
Streptococcus agalactiae (Group B Streptococcus) | ||
Penicillin | Oral therapy not suggested in infants | |
Streptococcus pyogenes (Group A Streptococcus) | ||
Penicillin Ampicillin | Penicillin Amoxicillin | |
Streptococcus pneumoniae (Pneumococcus) | ||
Penicillin-susceptible | Penicillin | Penicillin Amoxicillin |
Penicillin-nonsusceptible | Cefotaxime Ceftriaxone Clindamycin* Linezolid | Clindamycin* Linezolid |
Kingella kingae | ||
Penicillin Cefazolin Cefotaxime Ceftriaxone | Penicillin Cephalexin Cefixime | |
Haemophilus influenzae type b | ||
Cefotaxime Ceftriaxone Cefuroxime | Amoxicillin (if susceptible) Cefixime |
* If isolate is clindamycin-susceptible.
¶ Clindamycin should not be used even if D-test is negative.
Δ Daptomycin should not be used in children with concomitant pulmonary involvement. It is not approved for the treatment of osteoarticular infections in children; the appropriate dose has not been established.